Back to Stakeholders
Research, Drug Development & ManufacturingLead program: Pre-clinical

Transneural Therapeutics

2 Drug Candidates

Transneural Therapeutics is a Washington-based preclinical biotech spun out from CaaMTech in April 2025, developing AI-engineered non-hallucinogenic neuroplastogens for neuropsychiatric disorders. Lead candidate TN-001 is a dual 5-HT2A partial agonist/5-HT2B antagonist designed to deliver rapid antidepressant efficacy without hallucinations, potentially enabling outpatient dosing. TN-001 is in IND-enabling studies for MDD and PTSD, with preclinical data presented at ACNP 2026. CEO Charmaine Lykins brings experience from Karuna, ACADIA, and MapLight.

Drug Pipeline

2

TN-001

Pre-clinical
Major Depressive Disorder (MDD)PTSD

Dual 5-HT2A partial agonist/5-HT2B antagonist. AI-engineered scaffold. IND-enabling stage. Non-hallucinogenic; outpatient dosing potential. Preclinical synaptogenesis data at ACNP 2026.

TN-002

Discovery

One of 3 additional undisclosed pipeline programs. Neuroplastogen design.

Quick Facts

Type
Private Biotech
Founded
2025
Lead Stage
Pre-clinical
Website
Visit